WESTON, Mass. , March 11, 2025 /PRNewswire/ -- Body Vision Medical, a global leader in AI-powered intraoperative imaging, is proud to announce that its LungVision advanced imaging system has received regulatory approval from the Therapeutic Goods Administration (TGA) in Australia. This approval marks a significant milestone in the company's mission to improve early and accurate lung cancer diagnosis worldwide.

Lung cancer remains the leading cause of cancer-related deaths in Australia, with an estimated 14,500 new cases diagnosed annually. With the Australian Government Department of Health and Aged Care rolling out the National Lung Cancer Screening Program (NLCSP) to detect lung cancer at earlier stages, there is an increasing need for a definitive diagnostic pathway for patients with suspicious pulmonary nodules.

"This approval represents a major step forward in our global mission to transform lung cancer care," said Matt Baker, CEO at Body Vision Medical. "We are thrilled to partner with ParagonCare to make LungVision available in Australia and New Zealand, where the need for accurate, early-stage lung cancer diagnosis is more critical than ever."

LungVision, an AI-powered advanced imaging system that transforms any C-arm into a 3D imaging system, empowers physicians with real-time navigation and enhanced visualization to achieve more precise and accurate bronchoscopic biopsies. By enabling more confident diagnoses, LungVision supports the clinical goals of the NLCSP and has the potential to improve patient outcomes.

"We are excited to welcome Body Vision Medical's technology to our portfolio, as it strengthens our commitment to advancing augmented lung and respiratory medicine through cutting-edge AI," said Tiffany Chiew, General Manager Capital and Service at ParagonCare. "Body Vision's real-time imaging technology offers remarkable opportunities, significantly enhancing the chances for earlier cancer detection and ultimately improved lung cancer survival rates."

For more information about LungVision and its availability in Australia and New Zealand, please visit ParagonCare (paragoncare.com.au).

About Body Vision Medical

Body Vision Medical believes in saving lives through the democratization of innovative medical technology. LungVision provides AI-powered real-time image guidance to address the clinical need for early, definitive lung cancer diagnosis and to enable effective treatment of lung lesions via minimally invasive procedures.

Visit bodyvisionmedical.com to learn more and connect with us on LinkedIn.

About ParagonCare

A leader in healthcare technology, devices, software, consumables, pharmaceuticals, complimentary medicines and manufacturing of Blood Bank diagnostic reagents ParagonCare Limited (ASX: PGC) is dedicated to meeting the dynamic needs of the healthcare industry. By harnessing expertise, agility, and strong partnerships, ParagonCare is at the forefront of delivering innovative solutions that improve patient experiences and optimise healthcare workflows.

Contact:
Mike Hostetler
+1.651.366.9584
info@bodyvisionmedical.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/body-vision-medical-receives-regulatory-approval-for-lungvision-in-australia-expanding-access-to-ai-powered-advanced-imaging-for-lung-cancer-diagnosis-302397612.html

SOURCE Body Vision Medical